biotech acquisition rumorsbiotech acquisition rumors

A slow-growing U.S. economy is vulnerable to downside shocks, especially with the global economy expected to struggle. BioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. Quote. Got $1,000? It also has several pipeline candidates targeting oncology indications. The pipeline progress has been encouraging.

It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. The COVID-19 pandemic resulted in a shift in focus to development of vaccine and treatments for the deadly disease, which has taken 1.65 million lives so far. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Want the latest recommendations from Zacks Investment Research? Verona Pharma (VRNA): Granted specialty pharmaceutical company Nuance Pharma the development and commercialization rights for its ensifentrine in the Greater China region. Nancy Zambell has spent 30 years educating and helping individual investors navigate the minefields of the financial industry. If it gets approved, it could easily become a multi-billion dollar drug. MannKind now has a second product on the market as well via a licensing agreement with its partner on the project, United Therapeutics (UTHR). Heading into 2022, many drug giants have plump cash reserves and less fear that the Federal Trade Commission under President Biden will crack down on acquisitions. Its not unusual for rumors of a buyout offer to emerge a couple of days before the actual offer. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023. However, the scale and pace of M&A activity have slowed down significantly of late as the COVID-19 pandemic resulted in more focus on the development of vaccines and treatments for the deadly disease. When you join us, you get full access to our expertly curated collection of free investing reports, including 5 Best Stocks to Buy this Month, How to Find Undervalued Stocks, 10 Forever Stocks to Buy, and more. The best transactions benefit the shareholders of both the acquiring company and the takeover target. All those qualities are represented in our list of the top medtech acquisition targets for 2022. Updated March 13, 2023 By Jacob Bell In the business of drug development, deals can be just as important as scientific breakthroughs. I'm thinking Intellia (NTLA 0.47%) potentially being acquired by Regeneron (REGN 0.43%), and CRISPR Therapeutics (CRSP 1.34%) potentially being acquired by Vertex Pharmaceuticals (VRTX -0.09%). RTTNews->. Global M&A has hit a record $2.4 trillion, up 158% over 2020, according to a Refinitiv Deals Intelligence reportthe highest since the company began collecting data in 1980. Pfizer has agreed to buy Seattle-based Seagen for $43 billion in a blockbuster deal that would unite the pharmaceutical giant with a biotechnology company that pioneered a new type of tumor-killing medicine. BioMarin is one such drug developer. SVB Leerink estimates the Big Pharma companies firms like Pfizer, Johnson & Johnson, Novartis, and Roche will combine to have over $500 billion in cash by the end of 2022 that they could spend on M&A. Keith Speights: All right, Brian. But heres the thing Biogens drug requires IV infusion therapy and periodic MRIs to check for brain swelling and bleeding (two nasty side effects of lecanemab), while A2-73 is a pill and doesnt require periodic MRIs, a huge advantage even ignoring that A2-73 worked better. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. 4 Biotech Acquisitions We'd Like to See in 2022 By Keith Speights and Brian Orelli, PhD Jan 14, 2022 at 6:10AM Key Points If Bristol-Myers Squibb acquired Arrowhead is one of three major biotechs specializing in RNA interference, or RNAi, a technology that aims to block RNA code in cells that would build disease-causing proteins. Brian Orelli, PhD owns Seagen Inc. and Vertex Pharmaceuticals. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. Alexion Pharmaceuticals. About 87% of investors, for instance, expect an increase in mergers and acquisitions compared with last year, according to a JPMorgan survey conducted from November 22 to December 3. Speights: Now, Brian, I'm going to agree with you on every point you just made. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Anavex (AVXL), is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases with very encouraging results so far in Alzheimers, Parkinsons and Rett Syndrome. Mergers & Acquisitions (20,875) Money (78,723) New Companies (4,157) People (59,542) Preclinical (9,070) Real Estate (7,271) Regulatory (23,453) many in the life sciences are likely wondering if biotech layoffs will reach similar peaks. We think Trikafta still has room to grow. There's a company called Adicet Bio (ACET 2.56%), ticker there is ACET, I believe. XOMA Corporation, announced it has acquired the commercial payment and a portion of the milestone rights to IXINITY [coagulation factor IX ], which is marketed by Medexus Pharmaceuticals for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics. The other is an implantable permanent gel that is placed into the wall of the urethra and adds bulk to the weakened muscles and thus reduces or prevents leakage. And there are often rumors of other deals that never materialize. It is engaged in creating a pipeline of innovative gene therapies that have been developed both internally and through its collaboration, focused on cardiovascular diseases, with Bristol Myers-Squibb. NBIX (For disclosure, Joe Duarte own shares in AXNX. Specialty-pharma companies generally develop their own drugs, but Horizon has been beefing up its research and development efforts. The primary endpoints were the reduction in the decline of cognition (ADAS-COG) and activities of daily living (ADCS-ADL) at 48 weeks. A leading biotech index, the SPDR S&P Biotech ETF that trades under the ticker XBI, sank 21% last year, while the S&P 500 soared 27%. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. Rubraca competes with other PARP inhibitors like Lynparza and Zejula. I believe there is still plenty of room to run before the stock will finally be back at something that more closely resembles fair value. To make the world smarter, happier, and richer. Incyte has an attractive pharmaceutical portfolio comprising of Jakafi, a blockbuster drug for rare blood cancer indications, and 3 other marketed drugs, and a well-stocked pipeline. While the products being developed by Receptor Life are still several years away coming to market, they represent the potential for additional milestone payments and royalties as they work their way through the clinical trials process (and, knock on wood, commercialization at the end of said process). Horizon Therapeutics is a leading specialty-pharma company, a breed of business focused on helping distribute drugs that are difficult to store and could require extra patient instruction. But other times, the rumor fizzles along with the recent stock price gains. We looked at M&A target lists from analysts at Jefferies and investor surveys conducted by JPMorgan, Mizuho Securities, and RBC Capital Markets. The results may be announced approximately year end 2022. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. Moreover, stocks of these companies have not fully recovered the stock-market crash in March 2020, suggesting attractive valuations. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. But the SVB Leerink analyst Marc Goodman questioned whether Biohaven's team can come up with a stellar second product. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. Ally Biotech, a science-based company and provider of leading-edge bioactive cannabinoid delivery solutions, today announced the acquisition of the popular Not only does MannKind get paid to produce the product (plus a small mark-up) for United Therapeutics, it also receives a royalty on all sales of the product as well. Are some major acquisitions on the way in the biopharmaceutical industry this year? (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. Joe Cotton, Cottons Technically Speaking. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. The biotech also has a leading gene-therapy candidate to treat hemophilia, an inherited bleeding disorder, planning to file for FDA approval in the second quarter of 2022. Both AstraZeneca and Lilly, and other pharma companies that announced M&A deals earlier this year are particularly looking to diversify their pipeline into newer avenues of drug discovery and development. Here's How to Turn It Into a Lucrative Passive Income Stream, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Moreover, several companies in the biotech sector have taken a beating in 2020 due to the COVID-19 pandemic that has disrupted clinical studies and hurt sales of many drugs.

Invest better with The Motley Fool. If you're going to give me a quick up-front profit, I'm definitely going to take it and I'm not going to complain about it. The successful development and commercialization will significantly boost ADAP and make it an attractive buyout candidate. No. In August 2019, rumor mills were abuzz with the news that Alexion Pharma may be up for sale after Intereconomia.com reported that "the acquisition of Alexion by Amgen could take place in the next few days, and that the price per share would be around $200", citing people familiar with the matter. To read this article on Zacks.com click here. The 10 names below showed up on multiple of those lists, and they are sorted by current company valuation, from smallest to largest: Global Blood Therapeutics is on investors' and analysts' M&A lists because the company's sickle-cell drugs have a lot of potential the company is just not yet reaching it. The company continues to seek approval for Trikafta to treat different types of cystic fibrosis patients. The FDA decision on Pemigatinib is expected by May 30, 2020. *Stock Advisor returns as of January 10, 2022.

Biohaven's name has been bounced around as a potential acquisition target for the drugmaker Novartis, which has $21 billion in new funding after selling its Roche shares back to the company. But it has stumbled out of the gate, shelving two candidates for a liver disease called alpha-1 antitrypsin deficiency. The company has specialized in researching rare diseases and will celebrate its 25th anniversary in 2022. These 2 High-Yielding Dividend Stocks Are Near Their 52-Week Lows, 1 Hot Growth Stock to Buy Hand Over Fist Before It Soars 241%, According to Wall Street, This Warren Buffett ETF Could Take You From $5,000 to $87,000 With Next to No Effort. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 BMRN briefly touched $100.13 on February 5, 2019. WebPfizer, for one, could see $84 billion in total sales from its BioNTech-partnered COVID vaccine Comirnaty and its yet-to-be-authorized oral antiviral Paxlovid between 2021 Long before Moderna or BioNTech came along, Alnylam was pioneering how RNA would be used to treat diseases. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. As a result, the stock plummeted from $120 to $40. There have already been several big biotech licensing deals in Q1. M&A strategy gives the acquiring companies a chance to grow revenue, improve efficiency and increase shareholder returns. Earlier, Merck acquired erstwhile Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 billion to build its rare diseases portfolio. Denali Therapeutics (DNLI): Announced that its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with cutaneous lupus erythematosus (CLE). These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. The Company submitted a More Bank Failures If Congress & Biden Cant Cut A Debt Deal. Insider identified 10 biotechs that are prime takeover targets, according to analysts and investors. The companys cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors, next-generation Tumor Infiltrating Lymphocytes (TiLs) where a patients own T-cells are co-administered with next-generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. The stock is down 10.5% so far this year. That drug, called adagrasib, targets a genetic mutation called KRAS that is found in lots of cancers but has been thought to be untreatable with drugs. Insiders apparently think Simufilam works, because two Directors spent their hard earned cash buying the stock in August of 2022. There were a few, but not as many. Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies, sitting on huge piles of cash, prefer to buy innovative small/mid cap biotech companies to build out their pipelines. SunMed announced it has entered into a definitive agreement with Vyaire Medical, under which SunMed will acquire Vyaires business unit that manufactures and markets respiratory and anesthesia consumables focused on airway management and operative care. Just briefly, very quickly, I think Biogen (BIIB 0.99%) needs to make an acquisition -- ticker for Biogen is BIIB. Hospitals and health systems completed just seven mergers and acquisitions involving 20 hospitals in the third quarter of 2021. We understand your email address is private. Here's How to Turn It Into a Lucrative Passive Income Stream, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Knocking tech deals off their pedestal in May (although tech deals delivered an impressive $145.8 billion from January-May) is the media and entertainment sector, which accounted for 29% of Mays announcements. selling its Roche shares back to the company, continually surpassed analysts' expectations, handed sales and marketing of the drug over to Amgen in June, the first drug for the genetic cause of dwarfism, beefing up its research and development efforts. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly.

AnaBios Corporation today announced the acquisition of Cell Systems, a human primary cell and cell culture media company located in Kirkland, Washington. BioMarin could give a drugmaking giant an infusion of experimental and approved medicines. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Sales of both continue to grow steadily. The company also announced completion of drug administration in an open-label study of Simufilam for approximately 200 patients designed to evaluate long-term drug safely and to measure cognitive changes over 12 months. Biocom California, the association representing the life science industry of California, issued the following statement regarding their application to intervene in support of Illuminas challenge to the European Commissions jurisdiction over the acquisition of GRAIL. 2 Stocks to Buy Now. This product (Tyvaso DPI) has only been on the market for a few months, but it is already showing signs of becoming a blockbuster.

Cytokinetics has two experimental heart drugs that could catch Big Pharma's attention. Sign up for notifications from Insider! Pharma giants are expected to end 2022 with as much as $500 billion in cash, according to analysts. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. In addition, the company is advancing treatments for other ailments, including a genetic disease called alpha-1 antitrypsin deficiency and sickle cell disease. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. As has been the case for a number of years now, MNKD is considered a very strong buy under $5 and a buy under $10. The accounting firm PwC expects to see deals throughout the year in the $5 billion to $15 billion range, with pharma companies aiming to bring in new drugs that can grow into serious moneymakers later this decade. CEO Reshma Kewalramani said last year that she was looking for mid- to late-stage drug candidates to buy and fold into Vertex's pipeline. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Brian Orelli, PhD owns shares of Vertex Pharmaceuticals. Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for stay at home technologies. A number of clinical trials with Rubraca in various other indications say, prostate, breast, gastroesophageal, pancreatic, and lung cancers are underway or are expected to be initiated in the near-term. Stock of this Zacks Rank #3 company is down 33.6% year to date. BioMarin has six commercially approved rare disease drugs with some more in the pipeline. Nancy has worked with MoneyShow.com for many years as an editor and interviewer for their on-site video studios. Good News For Black Workers And A Goldilocks Job Market Are Good News For The Economys Stability, Eras Tour Could Net Taylor Swift $500 Million To $1.5 Billion. While rare, the drug is a big seller, with an expected $1.4 billion of revenue this year, up 30%-ish from last year, and more important, management sees a ton of opportunity just in its core area, with more than a half million undiagnosed patients in the U.S. alone (it thinks only 15% are both diagnosed and on treatment), so the potential is there for Ingrezza sales to easily more than double over time. Got $1,000? Director Richard Barry bought Several larger deals, on the scale of $50 billion or more, are also likely, PwC analysts wrote in a December 2021 report. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. The biotech industry could use the much-needed jolt. Mergers and acquisitions have roared back this year, with potential takeover targets everywhere. Companies that have a product portfolio/pipeline of rare disease drugs are in great demand as it is a less competitive space and the expensive treatments can bring in huge profits. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Stay up to date with what you want to know. That's the downside there. Get news straight to your inbox by signing up for our free eNewsletters, Select Medical Signs Agreement to Acquire Vibra Hospital of Richmond, AnaBios Acquires Cell Systems, Expands Human Cell Portfolio for Drug Discovery, Crown Bioscience Announces Transaction Closing of Indivumeds Service Business and Supporting Biobank, BioNTech Adds Two ADCs in Second Deal in as Many Months, Nova Research Laboratories, LLC announces acquisition of CiPA Lab, SK Capital completes acquisition of Apotex, a global leader in affordable pharmaceuticals, Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America, Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America, Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America, XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio, Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board, Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies, SunMed to Acquire Respiratory and Anesthesia Consumables Business of Vyaire Medical, Biocom California Statement on Illuminas Proposed Acquisition of GRAIL, MacuHealth and IOSA Joint Venture Acquires the Howard Foundation's Patent Portfolio, Morphogenesis Inc. Acquires THURA Biopharmas First-in-Class Antibody Drug Conjugates (ADCs) Technology Designed to Overcome Acquired Resistance to Cancer Immunotherapy, BIMINI HEALTH TECH ACQUIRES EXCLUSIVE LICENSE TO ACELLULAR DERMAL MATRIX PRODUCT PORTFOLIO. Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nations leading newsletter advisors. Keith Speights: Let's switch gears. Progress toward its potential approval may attract acquisition offers. Learn More. Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc. Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets. For three months in a row, deals have topped $500 billion. Type a symbol or company name. We've just talked about two deals that have been announced this week. We expect other pharma companies to follow suit to boost their pipeline amid rising competition and dwindling sales of legacy drugs. This newer avenue of treatment also has potential to earn high revenues as very few companies have been successful in developing an effective gene therapy. First I need to point out two very important things: 1) There was a delay in getting the data from one of the trial sites that resulted in the company only getting the data from the third party statistical analysis company just 1 day before it was on the schedule to present at the CTAD Alzheimers conference. But Brian, is there a biotech buyout that you would really like to see? I'm not sure. Medigene (MGD1.DE/MDGEF): German company partnered with bluebird bio Inc. on TCR-modified T-cell programs for multiple indications, including intracellular tumor antigens that arent addressable with CAR-T therapeutics. Now, let's take a speculative twist in our discussion about acquisitions. 2022 M&A activity in the life sciences sector failed to meet expectations, but Amgens recent $26.4 million buy-out of Horizon Therapeutics may be a sign of Opinion: 5 biotech buyout candidates you should look at right now - MarketWatch Jeff Reeves looks at five biotechs that might be buyout candidates in the wake of the big Juno deal. Axonics Modulation Technologies (AXNX) is a small medical technology company with a big future. Global M&A has hit a record $2.4 trillion, up 158% over 2020, according to a Refinitiv Deals Intelligence reportthe highest since the company began collecting data in 1980. Perhaps the most important fact to consider is that as the population ages and chronic conditions such as diabetes increase, so does the incidence of incontinence. Activision Blizzard's proposed $68.7 billion acquisition by Microsoft is looking more likely to succeed. The results of its ongoing Phase 3 clinical program are expected to come out in mid-2024. /Eisais 27% slowing of cognitive decline recently reported for lecanemab.